José Cardona

ORCID: 0000-0001-6206-653X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • Colorectal and Anal Carcinomas
  • Toxoplasma gondii Research Studies
  • Bone health and osteoporosis research
  • Diabetes Treatment and Management
  • Multiple and Secondary Primary Cancers
  • Erythropoietin and Anemia Treatment
  • Helminth infection and control
  • Hormonal Regulation and Hypertension
  • Genetic factors in colorectal cancer
  • Dialysis and Renal Disease Management
  • Diet and metabolism studies
  • Diabetes Management and Research
  • Iron Metabolism and Disorders
  • SARS-CoV-2 detection and testing
  • Diabetes and associated disorders
  • Lipoproteins and Cardiovascular Health
  • Colorectal Cancer Surgical Treatments
  • Veterinary Oncology Research
  • Animal Behavior and Welfare Studies
  • Healthcare Systems and Public Health
  • Infectious Diseases and Mycology
  • Public Health and Environmental Issues

University of Caldas
2006-2023

Bayer (Germany)
2022

Harvard University
2021

Franciscan Health
2021

Massachusetts General Hospital
2021

Georgetown University
2021

Larkin University
2020-2021

The University of Texas at Austin
2021

United States Army Combat Capabilities Development Command
2020

Eli Lilly (United States)
2020

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, prevent hospitalization.MethodsIn this ongoing phase trial involving outpatients with recently diagnosed or moderate Covid-19, we randomly assigned 452 patients receive a single intravenous infusion of neutralizing antibody...

10.1056/nejmoa2029849 article EN New England Journal of Medicine 2020-10-28

Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19.To determine the effect of bamlanivimab monotherapy and combination therapy with etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild moderate COVID-19.The BLAZE-1 study is randomized phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive SARS-CoV-2 infection had 1 or more...

10.1001/jama.2021.0202 article EN JAMA 2021-01-21

BackgroundPatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive and may limit progression complications.MethodsIn this phase 3 trial, we randomly assigned, in a 1:1 ratio, cohort of ambulatory patients mild or moderate Covid-19 who were high to receive single intravenous infusion either combination agent (2800...

10.1056/nejmoa2102685 article EN New England Journal of Medicine 2021-07-14

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied relationship among anti-spike ectodomain (anti-ECD), anti–receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by in vitro using convalescent plasma samples from 68 patients with COVID-19. report a strong positive correlation between both anti-RBD anti-ECD...

10.1172/jci141206 article EN Journal of Clinical Investigation 2020-09-10

Based on interim analyses and modeling data, lower doses of bamlanivimab etesevimab together (700/1400 mg) were investigated to determine optimal dose expand availability treatment.This Phase 3 portion the BLAZE-1 trial characterized effect with overall patient clinical status virologic outcomes in ambulatory patients ≥12 years old, mild-to-moderate coronavirus disease 2019 (COVID-19), ≥1 risk factor for progressing severe COVID-19 and/or hospitalization. Bamlanivimab or placebo infused...

10.1093/cid/ciab912 article EN cc-by-nc-nd Clinical Infectious Diseases 2021-10-27

Newly emerged pathogens such as SARS-CoV-2 highlight the urgent need for assays that detect levels of neutralizing antibodies may be protective. We studied relationship between anti-spike ectodomain (ECD) and anti-receptor binding domain (RBD) IgG titers, virus neutralization (VN) titers generated by two different in vitro using convalescent plasma samples obtained from 68 COVID-19 patients, including 13 who donated multiple times. Only 23% (16/68) donors had been hospitalized. also 16...

10.1101/2020.06.08.138990 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2020-06-09

Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate the efficacy and safety abaloparatide microstructured transdermal system (abaloparatide-sMTS) as an alternative SC formulation. This phase 3, noninferiority (NCT04064411) randomly assigned postmenopausal women with osteoporosis (N = 511) 1:1 open-label daily via abaloparatide-sMTS or injection 12 months. primary comparison between...

10.1002/jbmr.4877 article EN cc-by Journal of Bone and Mineral Research 2023-07-07

ABSTRACT Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, clinical fractures compared placebo. The for the Treatment Men Osteoporosis (ATOM; NCT03512262) study evaluated efficacy safety abaloparatide placebo men. Eligible men aged 40 to 85 years were randomized 2:1 daily subcutaneous injections 80 μg or 12 months. primary endpoint was change from baseline lumbar spine BMD. Key secondary...

10.1002/jbmr.4719 article EN cc-by Journal of Bone and Mineral Research 2020-12-01

Experimental and in vitro studies have related glycemic variability (GV) with activation of oxidative stress, which could be involved the micro- macrovascular damage found diabetes mellitus acute complications such as hypoglycemia. Some GV indexes are currently integrated specialized Web sites for analysis assessment patients through telemedicine. We aimed to identify impact telemedicine on metabolic control prepubescent type 1 (T1DM).Eighty between 6 10 years old were eligible enrollment....

10.1089/dia.2012.0243 article EN Diabetes Technology & Therapeutics 2013-01-05

Abstract Aims Albuminuria is associated with abnormalities in the nitric oxide (NO)–soluble guanylyl cyclase (sGC)–cyclic guanosine monophosphate pathway. We assessed safety and efficacy of NO‐independent sGC activator BI 685509 patients diabetic kidney disease albuminuria. Materials methods In this Phase Ib trial (NCT03165227), we randomized type 1 or 2 diabetes, estimated glomerular filtration rate (eGFR) 20–75 mL/min/1.73 m urinary albumin:creatinine ratio (UACR) 200–3500 mg/g to oral (1...

10.1111/dom.15099 article EN cc-by-nc Diabetes Obesity and Metabolism 2023-05-25

The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has sparked concern over the continued effectiveness existing therapeutic antibodies vaccines. Hence, together with increased genomic surveillance, methods to rapidly develop assess effective interventions are critically needed. Here we report discovery neutralizing isolated from COVID-19 patients using a high-throughput platform. Antibodies were identified unpaired donor B-cell serum repertoires yeast...

10.1101/2021.04.07.438849 preprint EN public-domain bioRxiv (Cold Spring Harbor Laboratory) 2021-04-08

The first cases of the coronavirus disease 2019 (COVID-19) were reported in Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy. However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe option for COVID-19 patients both moderate severe disease.

10.4103/2452-2473.309139 article EN cc-by-nc-sa Turkish Journal of Emergency Medicine 2021-02-12

La pythiosis cutanea equina es una enfermedad cronica, granulomatosa, pruriginosa y rapidamente progresiva, que ocurre en regiones con temperaturas varian de clima templado a caliente (tropical subtropical) causada por el oomiceto Pythium insidiosum. En la Costa Atlantica colombiana, se ve favorecida las condiciones medioambientales inundaciones. El objetivo del presente estudio fue determinar frecuencia presentacion caballos produccion explotaciones ganaderas departamento Cordoba, Colombia....

10.15446/rfmvz.v61n1.43882 article ES cc-by-nc-sa Revista de la Facultad de Medicina Veterinaria y de Zootecnia 2014-06-05

A neosporose tem grande importância em bovinos, e sua patogênese neste hospedeiro, termos gerais, está esclarecida, porém, equídeos é pobremente conhecida. Na Colômbia ainda não foram reportados anticorpos Anti-Neospora spp. equídeos, sendo assim objetivou-se no presente estudo avaliar a ocorrência do parasito jumentos (Equus asinus) de fazendas que apresentavam risco da doença nestes animais. Foram utilizados 56 animais estado Sucre (Colômbia), escolhidos aleatoriamente dentro das...

10.1590/1678-41627002 article PT cc-by Arquivo Brasileiro de Medicina Veterinária e Zootecnia 2014-04-01

El objetivo del trabajo fue contribuir al conocimiento de la seroepidemiología Neospora caninum y determinar los niveles sarcocystina en bovinos, con alteraciones reproductivas. Se evaluaron 162 sueros bovinos 28 caninos, procedentes fincas, localizadas el municipio Montería, mediante ELISA. realizó un análisis descriptivo información obtenida cada animal; resultados, se interpretaron acuerdo a las variables localización predio, edad, tipo sistema productivo, historia abortos o repetición...

10.31910/rudca.v18.n2.2015.166 article ES cc-by-nc Revista U D C A Actualidad & Divulgación Científica 2015-12-31

La Babesiosis equina o piroplasmosis equina, enfermedad que se transmite a los caballos por las garrapatas, es la principal restricción internacional para movilización de equinos. Es producida protozoos Theileria equi y Babesia caballi. Además caballos, afecta mulas, asnos cebras . Por medio muestreo conveniencia, implementó un estudio transversal, donde seleccionaron seis pesebreras en Montería (Córdoba), recolectaron 126 muestras sangre equinos ( Equus ferus caballus ), determinó el...

10.31910/rudca.v16.n2.2013.918 article ES cc-by-nc Revista U D C A Actualidad & Divulgación Científica 2013-12-31

Resumen Objetivo: determinar la frecuencia de presentación otitis parasitaria clínica por nematodos Rhabditiformes (Rhabditis spp.) en seis explotaciones raza Gyr Córdoba, Colombia. Métodos: se realizó un estudio descriptivo prospectivo animales conveniencia, entre los meses junio y octubre 2010. Se recolectaron muestras cerumen con hisopos conductos auditivos externos 155 bovinos. Resultados: causada Rhabditis spp. fincas Córdoba fue del 63.2%. Conclusión: las manifestaciones clínicas...

10.17533/udea.rccp.324785 article ES cc-by-nc-sa Revista Colombiana de Ciencias Pecuarias 2012-09-19

En este reporte se documenta un caso clínico de tumor venéreo transmisible (TVT) localización cutánea en canino femenino virgen.

10.21897/rmvz.1053 article ES cc-by-sa Revista Mvz Córdoba 2017-09-12

ANTECEDENTES: El cáncer de próstata (CP) ocupa los primeros lugares tanto en USA como países desarrollo. En registros Oncólogos del Occidente SA Colombia, el sexto lugar la población general y segunda neoplasia sexo masculino. MATERIALES Y MÉTODOS: Estudio descriptivo 404 pacientes con entre 12000 tratados desde Enero 1997 hasta Junio 2012. RESULTADOS: La media edad fue 69 años, 73% 61-80 años; 56% estadio clínico II. 37% Gleasson menor a 6; 30% PSA 4-10 ng/ml; 36% algún tipo tratamiento...

10.36104/amc.2015.447 article ES cc-by Acta Médica Colombiana 2015-08-02

Dentro del género Bos indicus , las razas Indubrasil y Gyr son más susceptibles a la otitis parasitaria por Rhabditis bovis . El ganado Gyr, sus características zootécnicas en el Caribe colombiano, ha sido seleccionado para producción de leche. objetivo presente investigación fue determinar prevalencia sp., bovinos empresas ganaderas Córdoba, Colombia. Se implementó un estudio descriptivo prospectivo conveniencia, donde se recolectaron hisopados cerumen los conductos auditivos externos, 136...

10.31910/rudca.v19.n1.2016.121 article ES cc-by-nc Revista U D C A Actualidad & Divulgación Científica 2016-06-30

12017 Background: Breast cancer stage IV is a common diagnosis in our developing countries so we follow this specific group for knowing its behavior the Instituto Oncologico ION S.A. from Manizales with 1,000,000 people of influence. Methods: It was retrospective analysis beginning records order to extract breast population and them they were up December 2006. Results: The accrued 888 patients January 1995 2006 50 (5.63%) Stage IV; 100% female; median age 56 (range 32–93. sd:14.374); Urban...

10.1200/jco.2008.26.15_suppl.12017 article EN Journal of Clinical Oncology 2008-05-20
Coming Soon ...